Patent intelligence · US
US 11945822
Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase
Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase
Patent details — US 11945822
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 2, 2024
- Expiration
- Mar 28, 2044
- Applicant
- Lead Discovery Center GmbH
- Claims
- 20
- CPC classes
- A61P, A61P29/00, A61P31/00, A61P35/00
Quick answer
US 11945822 (Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase) is held by Lead Discovery Center GmbH. Status: granted. Granted Apr 2, 2024. Expires Mar 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lead Discovery Center GmbH
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P29/00, A61P31/00, A61P35/00, A61P35/02, A61P37/00
More from Lead Discovery Center GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 11945822?
US 11945822 (Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase) is held by Lead Discovery Center GmbH. Status: granted. Granted Apr 2, 2024. Expires Mar 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11945822?
Lead Discovery Center GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 11945822 expire?
Our index shows an expiration date of Mar 28, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.